Trial Profile
A Study to Evaluate the Efficacy and Safety Everolimus and Mizoribine Based CNI Minimization Immunosuppressant Therapy for De Novo Kidney Transplant Recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Ciclosporin (Primary) ; Everolimus (Primary) ; Mizoribine (Primary) ; Prednisolone (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 23 Dec 2015 New trial record